Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) saw an uptick in trading volume on Friday . 2,316,811 shares were traded during mid-day trading, an increase of 282% from the previous session’s volume of 606,885 shares.The stock last traded at $0.29 and had previously closed at $0.28.
A number of research firms recently weighed in on CYTX. Maxim Group restated a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, April 1st. ValuEngine downgraded Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.
The stock has a market capitalization of $4.72 million, a price-to-earnings ratio of -0.17 and a beta of 2.13. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.46 and a quick ratio of 0.30.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.02. The company had revenue of $0.70 million during the quarter. Cytori Therapeutics had a negative return on equity of 272.70% and a negative net margin of 242.60%.
Institutional investors have recently made changes to their positions in the business. Barclays PLC increased its stake in Cytori Therapeutics by 724.4% in the 4th quarter. Barclays PLC now owns 99,747 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 87,647 shares during the period. Virtu Financial LLC increased its stake in Cytori Therapeutics by 236.8% in the 1st quarter. Virtu Financial LLC now owns 141,209 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 99,279 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Cytori Therapeutics by 81.9% in the 1st quarter. Renaissance Technologies LLC now owns 338,712 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 152,464 shares during the period. 4.08% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Cytori Therapeutics (CYTX) Sees Strong Trading Volume” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/05/24/cytori-therapeutics-cytx-sees-strong-trading-volume.html.
About Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.
See Also: What is a Derivative?
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.